SEC Tracker
Get the app

Revolution Medicines RVMD

Revolution Medicines reported a $407.46 million net loss

Form
10-Q
Filed
Importance
Notable
  1. Revenue of $197.56 million for the three months ended Sep 30, 2026
  2. Diluted EPS of -$1.90 for the three months ended Sep 30, 2026
  3. Cash and equivalents of $615.91 million as of Sep 30, 2026

Written from the 10-Q on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Revolution Medicines files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025
  2. Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
  3. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  4. Repligen RGEN public float $6.0B, Jun 30, 2025
  5. Madrigal Pharmaceuticals MDGL public float $5.6B, Jun 30, 2025